CR20130632A - El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico - Google Patents
El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéuticoInfo
- Publication number
- CR20130632A CR20130632A CR20130632A CR20130632A CR20130632A CR 20130632 A CR20130632 A CR 20130632A CR 20130632 A CR20130632 A CR 20130632A CR 20130632 A CR20130632 A CR 20130632A CR 20130632 A CR20130632 A CR 20130632A
- Authority
- CR
- Costa Rica
- Prior art keywords
- mat3
- prolactin
- receiver
- neutralizing antibody
- therapeutic use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
El anticuerpo neutralizador del receptor de prolactinaMat3. Fragmentos de unión al antígeno de éste. Composicionesfarmacéuticas que contienen dicho anticuerpo o dichosfragmentos de unión al antígeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20130632A true CR20130632A (es) | 2014-02-04 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20130632A CR20130632A (es) | 2011-06-03 | 2013-12-03 | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (es) |
| EP (2) | EP2530089A1 (es) |
| JP (1) | JP5859641B2 (es) |
| KR (1) | KR101920521B1 (es) |
| CN (1) | CN103764679B (es) |
| AP (1) | AP2013007266A0 (es) |
| AR (1) | AR086631A1 (es) |
| AU (1) | AU2012264765B2 (es) |
| BR (1) | BR112013030995B1 (es) |
| CA (1) | CA2837736C (es) |
| CL (1) | CL2013003459A1 (es) |
| CO (1) | CO6852025A2 (es) |
| CR (1) | CR20130632A (es) |
| CU (1) | CU20130163A7 (es) |
| CY (1) | CY1117660T1 (es) |
| DK (1) | DK2714740T3 (es) |
| DO (1) | DOP2013000285A (es) |
| EA (1) | EA029316B1 (es) |
| EC (1) | ECSP13013063A (es) |
| ES (1) | ES2572215T3 (es) |
| HK (1) | HK1195081A1 (es) |
| HR (1) | HRP20160506T1 (es) |
| HU (1) | HUE028775T2 (es) |
| IL (1) | IL229504B (es) |
| MA (1) | MA35237B1 (es) |
| ME (1) | ME02659B (es) |
| MX (1) | MX343683B (es) |
| PE (1) | PE20141158A1 (es) |
| PL (1) | PL2714740T3 (es) |
| RS (1) | RS54727B1 (es) |
| SG (1) | SG195060A1 (es) |
| SI (1) | SI2714740T1 (es) |
| TN (1) | TN2013000501A1 (es) |
| TW (1) | TWI548649B (es) |
| UY (1) | UY34116A (es) |
| WO (1) | WO2012163932A1 (es) |
| ZA (1) | ZA201309683B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013232266A1 (en) | 2012-03-14 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| KR20150100881A (ko) * | 2012-12-24 | 2015-09-02 | 애브비 인코포레이티드 | 프롤락틴 수용체 결합 단백질 및 이의 용도 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| US10925971B2 (en) | 2016-11-29 | 2021-02-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating PRLR positive breast cancer |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| BR112020000378A2 (pt) | 2017-07-10 | 2020-07-21 | Bayer Pharma Aktiengesellschaft | anticorpo de receptor de prolactina para perda capilar padrão masculino e feminino |
| ES2973864T3 (es) * | 2017-08-10 | 2024-06-24 | Grifols Diagnostic Solutions Inc | Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| EP2423231A3 (en) * | 2006-08-18 | 2012-05-30 | Novartis AG | PRLR-specific antibody and uses thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active IP Right Grant
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en active Application Filing
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active Pending
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2014
- 2014-08-18 HK HK14108441.2A patent/HK1195081A1/zh unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-05-12 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| CL2017001217A1 (es) | Conjugados de droga de anticuerpos. | |
| BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
| PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| CL2011002877A1 (es) | Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| BR112015003757A2 (pt) | anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| CR20140382A (es) | Anticuerpos anti-lrp5 y metodos de uso | |
| BR112016029860A2 (pt) | conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
| AR089084A1 (es) | Anticuerpos dirigidos al receptor del factor de crecimiento epidermico humano 3 (her3) dirigidos contra el dominio ii del her3 | |
| BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
| EA201391199A1 (ru) | Композиции из hyr1-производных и способы лечения ими |